Roche Holding AG (LTS:0QOK)
CHF 248.4 1.25 (0.51%) Market Cap: 201.45 Bil Enterprise Value: 231.01 Bil PE Ratio: 18.78 PB Ratio: 6.84 GF Score: 84/100

Roche Holding AG Virtual Event on Key Ophthalmology Data Presented at the Angiogenesis 2022 Meeting Transcript

Feb 14, 2022 / 03:30PM GMT
Release Date Price: CHF344 (-2.27%)
Operator

Ladies and gentlemen, welcome to Roche Angiogenesis 2022 Meeting. My name is Marco, and I'm the technical operator for today's call. Kindly note that the webinar is being recorded. (Operator Instructions)

At this time, it is my pleasure to introduce you to Bruno Eschli, Head of Investor Relations. Bruno, the stage is yours.

Bruno Eschli

Thanks, Marco. Can I have the first slide, please? Next one, please. So welcome to our event, and let me quickly guide you through today's agenda. We have 3 speakers with us. So first of all, Nilesh Mehta, our global franchise head in ophthalmology. He will present an update on our overall franchise strategy. And then we have Christopher Brittain with us, our Vice President and Global Head of Ophthalmology Product Development, who will provide you an update on our growing clinical development pipeline. And finally, last but not least, we have Nancy Holekamp with us, a well-known retina specialist and also a Vabysmo clinical investigator, who will lead us through the 2-year data of Vabysmo and Susvimo, which we have just

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot